Article Per Year (5 Year)
p-Index From 2019 - 2024
0
P-Index
This Author published in this journals
All Journal Journal of Medicine and Health
Antonius Janes Ridwan, Antonius Janes
Unknown Affiliation
Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
ANALYSIS OF IMMUNOEXPRESSION OF ESTROGEN RECEPTOR BETA AND EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER (EMMPRIN) ON TESTICULAR SEMINOMAS NONRECURRENCE AND RECURRENCE Ridwan, Antonius Janes; Suryanti, Sri; Hassan, Abdul Hadi; Hernowo, Bethy S
Journal of Medicine and Health Vol 1, No 2 (2015)
Publisher : Maranatha Christian University

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The most common malignancy of testis is seminoma with prognosis that is not always good because of high recurrence rate and death cases. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a glycoprotein adhesion molecules which plays a role in tumor cell invasion and metastasis as evidenced by immunohistochemistry method in several types of tumor cells and tissue that shows the correlation to the clinical progessivity.This study was conducted by observational descriptive analytics with each seven cases of seminoma nonrecurrences and recurrences diagnosed histopathologically from Dr.Hasan Sadikin Hospital, Advent Hospital and St.Borromeus Hospital in Bandung. This study shows that immunoexpression of estrogen receptor beta is not higher in testicular seminoma recurrence compared with nonreccurence. There was no higher imunoexpression of EMMPRIN receptor on testicular seminoma recurrence compared with nonrecurrence; besides, there was no relationship between immunoexspression of estrogen receptor beta and EMMPRIN in testicular seminoma nonrecurrence and recurrence.In conclusion, immunoexpression estrogen receptor beta expressed in all testicular seminoma, so that the patient could be given an alternative therapy and immunoexspression EMMPRIN, cannot be used to predict a recurrence in patients with seminoma who has received complete therapy.                                                        Keywords: EMMPRIN, Estrogen Receptor Beta, Seminoma Testis nonrecurrence and recurrence
ANALYSIS OF IMMUNOEXPRESSION OF ESTROGEN RECEPTOR BETA AND EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER (EMMPRIN) ON TESTICULAR SEMINOMAS NONRECURRENCE AND RECURRENCE Ridwan, Antonius Janes; Suryanti, Sri; Hassan, Abdul Hadi; Hernowo, Bethy S
Journal of Medicine and Health Vol. 1 No. 2 (2015)
Publisher : Universitas Kristen Maranatha

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (425.175 KB) | DOI: 10.28932/jmh.v1i2.507

Abstract

The most common malignancy of testis is seminoma with prognosis that is not always good because of high recurrence rate and death cases. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a glycoprotein adhesion molecules which plays a role in tumor cell invasion and metastasis as evidenced by immunohistochemistry method in several types of tumor cells and tissue that shows the correlation to the clinical progessivity.This study was conducted by observational descriptive analytics with each seven cases of seminoma nonrecurrences and recurrences diagnosed histopathologically from Dr.Hasan Sadikin Hospital, Advent Hospital and St.Borromeus Hospital in Bandung. This study shows that immunoexpression of estrogen receptor beta is not higher in testicular seminoma recurrence compared with nonreccurence. There was no higher imunoexpression of EMMPRIN receptor on testicular seminoma recurrence compared with nonrecurrence; besides, there was no relationship between immunoexspression of estrogen receptor beta and EMMPRIN in testicular seminoma nonrecurrence and recurrence.In conclusion, immunoexpression estrogen receptor beta expressed in all testicular seminoma, so that the patient could be given an alternative therapy and immunoexspression EMMPRIN, cannot be used to predict a recurrence in patients with seminoma who has received complete therapy.                                                        Keywords: EMMPRIN, Estrogen Receptor Beta, Seminoma Testis nonrecurrence and recurrence
Co-Authors Abdul Hadi Hassan, Abdul Hadi Bethy S Hernowo, Bethy S Sri Suryanti